New spinal fluid test may sharpen Alzheimer's diagnosis
NCT ID NCT02770482
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether measuring a protein called amyloid beta 1-40 in spinal fluid can help doctors diagnose Alzheimer's disease more accurately. Researchers collected spinal fluid from 204 people with memory problems. They want to see if adding this new measurement to existing tests reduces uncertainty in diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a more accurate spinal fluid test for Alzheimer's disease, helping doctors diagnose it with greater certainty.
- What could go wrong
- This is a completed study analyzing existing data, not a treatment trial. The new marker may not significantly improve diagnosis over current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu de Reims
Reims, 51092, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Could your heart hold the key to Alzheimer's prevention?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a Voice-Based app map healthy brain aging across 80 years?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can brain scans and gut bacteria reveal Alzheimer's secrets?